Global Pets Internal Dewormer Market Size By Type (Tablet, Powder), By Application (Dogs, Cats), By Region, And Segment Forecasts, 2023 to 2032

The Global Pets Internal Dewormer Market was valued at USD 2.1 billion in 2023 and is projected to reach USD 3.8 billion by 2031, growing at a CAGR of 7.5% during the forecast period (2023–2031). The growth is propelled by increasing pet ownership worldwide, heightened awareness of pet health, and growing demand for preventive veterinary care. Internal dewormers play a vital role in controlling and preventing parasitic infections, ensuring pets’ health and minimizing zoonotic risks to humans. The expanding availability of pet healthcare products through e-commerce and retail channels is also fueling market growth.

Drivers:

1. Rising Pet Ownership and Humanization of Pets:

A growing number of households globally are treating pets as family members, leading to increased spending on pet healthcare, including preventive treatments like internal dewormers.

2. Increasing Awareness of Zoonotic Diseases:

Heightened public awareness about diseases transmitted from animals to humans has spurred demand for regular deworming, supported by veterinary recommendations.

3. Veterinary Health Campaigns and Recommendations:

Public and private initiatives promoting animal health, including campaigns by veterinary associations and pet welfare organizations, are encouraging regular deworming practices.

Restraints:

1. Limited Access in Low-Income Regions:

In rural and underdeveloped areas, access to veterinary care and deworming products remains limited, hindering market penetration.

2. Lack of Compliance Among Pet Owners:

Despite awareness campaigns, many pet owners fail to adhere to recommended deworming schedules, reducing product effectiveness and slowing market growth.

Opportunity:

1. Growth of Online Veterinary Pharmacies:

The expansion of digital platforms for veterinary supplies allows broader product reach, particularly in remote or underserved areas.

2. Innovations in Palatable and Long-Acting Formulations:

Manufacturers are investing in R&D to create dewormers that are easier to administer, such as chewable tablets or flavored pastes, improving compliance.

3. Rising Demand in Emerging Markets:

Pet ownership is on the rise in regions like Asia-Pacific and Latin America, presenting untapped potential for internal dewormer products as veterinary infrastructure improves.

Market by System Type Insights:

The Tablets & Chewables segment held the largest market share in 2023. These formats are preferred due to ease of administration, improved palatability, and longer shelf life. Liquid Suspensions, ideal for puppies, kittens, and small breeds, are also gaining popularity, especially among new pet owners.

Market by End-use Insights:

The Companion Animal Clinics segment accounted for the largest market share in 2023, as these establishments provide the primary point of care for pets. Home-based treatment is the fastest-growing end-use segment, driven by the availability of OTC products and the convenience of treating pets without clinical visits.

Market by Regional Insights:

North America led the market in 2023 due to high pet ownership rates, well-established veterinary services, and strong consumer awareness. Asia-Pacific is projected to witness the fastest growth, supported by increasing pet adoption, growing disposable incomes, and expanding access to pet healthcare services in countries like China, India, and South Korea.

Competitive Scenario:

Key players in the Global Pets Internal Dewormer Market include Boehringer Ingelheim Animal Health, Zoetis Inc., Elanco Animal Health, Bayer AG, Virbac, Vetoquinol S.A., Ceva Santé Animale, Merck Animal Health, and Bimeda Inc. These companies are focusing on portfolio expansion, distribution partnerships, and the development of novel deworming formulations to maintain competitiveness.

In 2023, Zoetis introduced a new broad-spectrum internal dewormer targeting multiple gastrointestinal parasites in dogs and cats.

In 2024, Virbac expanded its pet care product line in Asia with improved palatable deworming solutions.

In 2025, Elanco announced a collaboration with veterinary telemedicine platforms to integrate deworming products into remote pet healthcare consultations.

Scope of Work – Global Pets Internal Dewormer Market

Report Metric Details

Market Size (2023) USD 2.1 Billion

Projected Market Size (2031) USD 3.8 Billion

CAGR (2023–2031) 7.5%

Market Segments By System Type (Tablets, Liquids, Pastes), By End-use (Clinics, Home)

Growth Drivers Pet humanization, zoonotic disease awareness, veterinary care expansion

Opportunities E-commerce, emerging markets, innovative formulations

Key Market Developments:

2023: Zoetis launched a chewable dewormer for cats with enhanced taste-masking technology.

2024: Bayer AG expanded its online veterinary product distribution in Southeast Asia.

2025: Ceva Santé Animale partnered with retail pharmacy chains to improve accessibility to OTC dewormers in Latin America.

FAQs:

1) What is the current market size of the Global Pets Internal Dewormer Market?

The market was valued at USD 2.1 billion in 2023.

2) What is the major growth driver of the Global Pets Internal Dewormer Market?

Increasing pet ownership and rising awareness of zoonotic diseases are major growth drivers.

3) Which is the largest region during the forecast period in the Global Pets Internal Dewormer Market?

North America is the largest region, while Asia-Pacific is expected to grow the fastest.

4) Which segment accounted for the largest market share in the Global Pets Internal Dewormer Market?

The Tablets & Chewables segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Pets Internal Dewormer Market?

Key players include Boehringer Ingelheim, Zoetis, Elanco, Bayer AG, Virbac, and Merck Animal Health.